# Erasca, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Erasca, Inc.).

## Overview

Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for cancers driven by the RAS/MAPK pathway. Its pipeline is built around targeting key signaling nodes, targeting RAS directly, and blocking escape mechanisms that emerge during treatment.

## Products & services

• Naporafenib (pan-RAF inhibitor)
• ERAS-0015 in-licensed oncology program
• ERAS-4001 in-licensed oncology program
• ERAS-12 acquired oncology program
• Clinical development of RAS/MAPK pathway therapies
• Erasca Ventures early-stage biotech investments

- **Clinical-stage oncology pipeline** (95%) — Drug candidates and combination regimens aimed at RAS/MAPK pathway-driven cancers.
- **External innovation and licensing** (3%) — In-licensed and acquired assets sourced from third parties to expand the pipeline.
- **Corporate venture investments** (2%) — Minority equity investments in early-stage biotechnology companies through Erasca Ventures.

- Naporafenib, a pan-RAF inhibitor in clinical development
- ERAS-0015, an in-licensed oncology program
- ERAS-4001, an in-licensed oncology program
- ERAS-12, an acquired oncology program
- Clinical development of RAS/MAPK pathway therapies
- Erasca Ventures equity investments in early-stage biotech

## Customers

Erasca does not currently sell approved products and has no commercial customer base today. Its future customers would be patients with RAS/MAPK-driven cancers, with treatment adoption driven by oncologists, cancer centers, and hospital systems if any candidate is approved. In the near term, the company’s counterparties are research partners, CROs, CMOs, licensors, and potential commercialization partners rather than end-market buyers.

- **Future oncology patients** (primary) — Patients with NRAS-mutated melanoma and other RAS/MAPK-driven solid tumors who would use approved therapies.
- **Oncology treatment centers** (primary) — Hospitals, cancer centers, and physician groups that would adopt and administer the drugs if approved.
- **Research and development partners** (secondary) — CROs, CMOs, consultants, and scientific advisors that execute trials and manufacturing work.
- **Licensing and collaboration counterparties** (secondary) — Biotech and academic partners that provide assets, IP, or commercialization support.

- Patients with RAS/MAPK-driven cancers are the eventual end users
- Oncologists and cancer centers would prescribe approved therapies
- Hospitals and integrated delivery networks would purchase and administer treatment
- CROs, CMOs, and scientific advisors support development execution
- Licensors and collaboration partners supply external pipeline assets

## Geography

Erasca is headquartered in the United States and currently conducts its business primarily through U.S.-based clinical development and corporate operations. Management has said it intends to commercialize in the United States first and potentially in Europe, while seeking partnerships in other regions beyond those markets. Because the company is still pre-commercial, geography mainly affects trial execution, licensing, and future launch planning rather than current sales mix.

- United States is the core operating base and first commercialization target
- Europe is a potential second launch market if approvals are obtained
- Other regions may be accessed through partnerships rather than direct sales
- Clinical development is globally sourced through external innovation and partners
- No disclosed country revenue because the company has no product sales

## Strategy

Erasca’s strategy is to build a focused precision oncology pipeline around the RAS/MAPK pathway and advance it through biomarker-driven clinical trials. The company also supplements internal discovery with in-licensing, acquisitions, and collaborations, while preserving worldwide development and commercialization rights where possible.

- **Advance naporafenib and other pipeline assets in biomarker-defined trials** (short-term) — Clinical proof-of-concept is required to create value and support future approvals.
- **Use precision oncology trial design to accelerate readouts** (medium-term) — Adaptive and basket/umbrella studies can improve speed and efficiency in heterogeneous cancers.
- **Expand the pipeline through external innovation** (medium-term) — In-licensing and acquisition broaden the addressable biology without relying only on internal discovery.
- **Prepare for eventual commercialization in the U.S. and Europe** (long-term) — A commercial infrastructure will be needed if any candidate is approved, and partnerships may reduce launch burden elsewhere.

- Advance RAS/MAPK pathway programs through clinical proof-of-concept
- Use adaptive, basket, umbrella, and master protocol trial designs
- Target upstream, direct RAS, and escape-route biology in parallel
- Source external assets through in-licensing and acquisitions
- Build U.S. commercialization capability and partner outside core markets

## Risks

Erasca is a pre-revenue biotech with a limited operating history, so its value depends on successful clinical development, regulatory approval, and future financing. The company also faces execution risk from trial delays, manufacturing dependence on third parties, cybersecurity exposure, and the possibility that it never generates meaningful product revenue.

- **Clinical development failure** [critical] — Pipeline value depends on proving safety and efficacy in human trials, which is inherently uncertain in oncology.
- **Financing risk** [high] — The company has no product sales and expects to fund operations through equity, debt, or collaborations.
- **Regulatory approval risk** [high] — Even positive clinical data may not translate into approval, delaying or preventing revenue generation.
- **Third-party manufacturing and vendor dependence** [high] — The company relies on CMOs, CROs, and external service providers for development and supply chain execution.
- **Cybersecurity and data integrity** [medium] — Loss or compromise of clinical trial data could delay regulatory filings and increase recovery costs.

- No approved products means no current product revenue
- Clinical trial failure or delay could eliminate pipeline value
- Additional capital may be needed before commercialization
- Third-party manufacturing and CRO dependence adds execution risk
- Cybersecurity incidents could disrupt trials and expose confidential data

## Accounting

Erasca’s financial reporting is dominated by R&D expense recognition, stock-based compensation, and valuation judgments around cash, marketable securities, and any acquired or in-licensed intangible assets. Because the company is pre-commercial, revenue recognition is minimal today, but future collaboration, license, or milestone accounting could become important if partnerships expand.

- **Research and development expense capitalization policy** — Quarterly operating results can swing with trial activity and vendor spend
- **Stock-based compensation** — Affects operating expenses and diluted share count
- **Fair value of marketable securities** — Can affect other income and liquidity presentation
- **License and acquisition accounting** — Can affect balance sheet intangibles and future impairment risk

- R&D costs are expensed as incurred, affecting operating loss timing
- Stock-based compensation is a meaningful non-cash expense for a biotech
- Cash and marketable securities valuation affects liquidity disclosure
- In-licensed or acquired programs may create intangible asset judgments
- Future collaboration or milestone revenue would require contract accounting

---

*Last updated: 2026-04-28T20:05:19.717274+00:00*